Synopsis
0
JDMF
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
FDA Orange Book
0
Canada
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
FDF
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CEP/COS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
DATA COMPILATION #PharmaFlow
NEWS #PharmaBuzz
Market Place
ABOUT THIS PAGE
75
PharmaCompass offers a list of Lercanidipine Hydrochloride API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Lercanidipine Hydrochloride manufacturer or Lercanidipine Hydrochloride supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Lercanidipine Hydrochloride manufacturer or Lercanidipine Hydrochloride supplier.
A Lerkamen manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Lerkamen, including repackagers and relabelers. The FDA regulates Lerkamen manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Lerkamen API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Lerkamen manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.
A Lerkamen supplier is an individual or a company that provides Lerkamen active pharmaceutical ingredient (API) or Lerkamen finished formulations upon request. The Lerkamen suppliers may include Lerkamen API manufacturers, exporters, distributors and traders.
click here to find a list of Lerkamen suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.
A Lerkamen DMF (Drug Master File) is a document detailing the whole manufacturing process of Lerkamen active pharmaceutical ingredient (API) in detail. Different forms of Lerkamen DMFs exist exist since differing nations have different regulations, such as Lerkamen USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Lerkamen DMF submitted to regulatory agencies in the US is known as a USDMF. Lerkamen USDMF includes data on Lerkamen's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Lerkamen USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Lerkamen suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Lerkamen Drug Master File in Korea (Lerkamen KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Lerkamen. The MFDS reviews the Lerkamen KDMF as part of the drug registration process and uses the information provided in the Lerkamen KDMF to evaluate the safety and efficacy of the drug.
After submitting a Lerkamen KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Lerkamen API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Lerkamen suppliers with KDMF on PharmaCompass.
A Lerkamen CEP of the European Pharmacopoeia monograph is often referred to as a Lerkamen Certificate of Suitability (COS). The purpose of a Lerkamen CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Lerkamen EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Lerkamen to their clients by showing that a Lerkamen CEP has been issued for it. The manufacturer submits a Lerkamen CEP (COS) as part of the market authorization procedure, and it takes on the role of a Lerkamen CEP holder for the record. Additionally, the data presented in the Lerkamen CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Lerkamen DMF.
A Lerkamen CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Lerkamen CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Lerkamen suppliers with CEP (COS) on PharmaCompass.
A Lerkamen written confirmation (Lerkamen WC) is an official document issued by a regulatory agency to a Lerkamen manufacturer, verifying that the manufacturing facility of a Lerkamen active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Lerkamen APIs or Lerkamen finished pharmaceutical products to another nation, regulatory agencies frequently require a Lerkamen WC (written confirmation) as part of the regulatory process.
click here to find a list of Lerkamen suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Lerkamen as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Lerkamen API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Lerkamen as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Lerkamen and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Lerkamen NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Lerkamen suppliers with NDC on PharmaCompass.
Lerkamen Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Lerkamen GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Lerkamen GMP manufacturer or Lerkamen GMP API supplier for your needs.
A Lerkamen CoA (Certificate of Analysis) is a formal document that attests to Lerkamen's compliance with Lerkamen specifications and serves as a tool for batch-level quality control.
Lerkamen CoA mostly includes findings from lab analyses of a specific batch. For each Lerkamen CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Lerkamen may be tested according to a variety of international standards, such as European Pharmacopoeia (Lerkamen EP), Lerkamen JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Lerkamen USP).
